Skip to main content

Shimadzu, Indigo BioSystems Partner on Clinical Mass Spec Workflows

NEW YORK (GenomeWeb News) – Shimadzu and Indigo BioSystems announced that they have formed a partnership for the development of clinical mass spectrometry workflows.

Under the partnership, the two firms will combine Shimadzu's mass spec instruments with Indigo's Ascent clinical analysis software, a platform for interpreting mass spec data and automatically reviewing that data for problematic results.

The partnership will focus on developing mass spec solutions for applications in clinical research, forensic toxicology, and drug development, the companies said.

The Ascent software is aimed at streamlining mass spec data review, automatically scanning data for outliers, which can then be passed on for manual expert review. By passing on only potential outliers for expert review, the software can improve turnaround time and reduce costs per sample.

Financial and other terms of the agreement, which was announced at the American Society for Mass Spectrometry annual meeting being held in Baltimore this week, were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.